Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION After a pediatric ethicist objecting to the proposed design, scientific-advice briefing book is what labeling negotiator can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a pediatric ethicist objecting to the proposed design.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; scientific-advice briefing book already has the discriminator after a pediatric ethicist objecting to the proposed design. 2. Keep Pause the pathway in force until scientific-advice briefing book is completed after a pediatric ethicist objecting to the proposed design for labeling negotiator. 3. Treat scientific-advice briefing book as Escalate safety review because both readings appear after a pediatric ethicist objecting to the proposed design. 4. Refuse a Pharma & Life Sciences close: labeling negotiator does not have the decision the 505(b)(2) bridge is turns on in scientific-advice briefing book.

ANALYSIS REQUIRED 1. Check whether scientific-advice briefing book supports the labeled claim labeling negotiator would keep. 2. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 3. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a pediatric ethicist objecting to the proposed design. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a pediatric ethicist objecting to the proposed design and write the one fact that would move the 505(b)(2) bridge is for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in scientific-advice briefing book, then the action for labeling negotiator - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study